newsfilter
← Latest News
PR Newswire·

MiniMed Delivers Strong Start to Fiscal Year 2027 with U.S. Growth Acceleration

MMED
  • MiniMed reported Q1 FY27 net sales of $843 million, representing 17% growth as reported and 16% organic growth.
  • U.S. net sales reached $240 million with 13% growth, driven by over 20% year-over-year increase in new pumps sold.
  • International net sales totaled $603 million, growing 18% as reported and 17% organic.
  • Worldwide New Pumps Sold increased 7.7% to approximately 34,000 units.
  • Worldwide CGM attachment rate rose to 69%, up by approximately 100 basis points quarter-over-quarter.
  • The MiniMed Flex™ pump launched in the U.S. with expanded coverage for Medicare beneficiaries.
  • The MiniMed Fit™ patch pump was submitted to the U.S. FDA ahead of schedule, with a full U.S. launch expected in Summer 2027.
  • The MiniMed Flex™ received its CE Mark ahead of the 2026 year-end target, with a European commercial launch planned for November.
  • Vivera™ fully-closed loop algorithm U.S. pivotal trial enrollment for T1 and T2 patients was completed.
  • IDE approval was granted for the next-gen extended wear MiniMed sensor, with pivotal trial enrollment expected this Fall.
  • MiniMed raised its FY27 organic revenue growth guidance to approximately 10.5% from a prior estimate of 10%.
  • The company reaffirmed its FY27 Adjusted EBITDA margin guidance of approximately 16%.